A carregar...
SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
Denosumab (DMAb) is a soluble inhibitor of RANKL and, therefore, does not incorporate into the bone matrix. Consistently, DMAb discontinuation is associated with the reversal of the effects attained with treatment. Concerns have been raised regarding possible increased vertebral fragility following...
Na minha lista:
| Publicado no: | J Endocr Soc |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Endocrine Society
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6552094/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-532 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|